CLINICAL TRIALS PROFILE FOR BOOSTRIX

All Clinical Trials for BOOSTRIX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02377349 ↗	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women	Completed	GlaxoSmithKline	Phase 4	2015-10-14	The purpose of this study is to assess the immunogenicity and safety of Boostrix™ when compared to a placebo given during 27-36 weeks of gestation in healthy women aged 18-45 years. Infants born to mothers enrolled in this study will be followed-up in two separate clinical studies: 201330 [DTPA (BOOSTRIX)-048 PRI] and 201334 [DTPA (BOOSTRIX)-049 BST: 048].
NCT02422264 ↗	Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Completed	GlaxoSmithKline	Phase 4	2016-01-22	The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies interfere with the immune response to primary vaccination with Infanrix hexa and a co-administered pneumococcal conjugate vaccine given as a part of this study in infants.
NCT02526394 ↗	Pertussis and Meningitis C Concomitant Vaccination in Adolescents	Completed	Public Health England	Phase 4	2013-09-01	The trial includes groups receiving various combinations of meningitis C and pertussis containing vaccines, to be administered concomitantly in adolescents due their school leaving booster vaccinations (as per UK routine immunisation schedule at 13-17 years of age). Immunogenicity and reactogenicity will be assessed.
NCT04138056 ↗	A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women	Active, not recruiting	GlaxoSmithKline	Phase 2	2019-11-05	The purpose of this study is to evaluate the safety, ability of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) to generate an immune response and the degree to which the vaccine can cause side effects, when administered alone and in combination with Boostrix vaccine in healthy non-pregnant women 18-45 years of age. Two dose levels of RSVPreF3 and 2 Boostrix [Diphtheria, Tetanus and acellular Pertussis (dTpa) vaccine] formulations (US and ex-US) will be evaluated. A 2nd dose of RSVPreF3 will be administered in an extension of the study to assess the durability of the immune response after the first dose vaccination, and to assess the safety and immunogenicity following a second dose vaccination of the RSVPreF3 maternal vaccine.
NCT05073003 ↗	A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants	Recruiting	GlaxoSmithKline	Phase 1/Phase 2	2021-10-06	The aim of the current clinical study is to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine will be first administered in adults 18 to 50 years of age in Europe. Subsequently, the vaccine will be administered to a shigellosis-endemic population in Africa, first in adults 18 to 50 years of age, then in children 24 to 59 months of age, and finally in infants 9 months of age. Infants will also receive a third vaccination. Three different doses of the vaccine [low (Dose A), medium (Dose B), and high (Dose C) amounts of antigen] will be evaluated using an age de-escalation approach (from least vulnerable adult population to most vulnerable paediatric population). The results of this study will allow the selection of the most appropriate dose for further vaccine development in infants 9 months of age, which is the main target age group for this vaccine.

Clinical Trial Conditions for BOOSTRIX

Condition Name

Condition Name for BOOSTRIX
Intervention	Trials
Dermatitis Atopic	1
Salmonella Infections	1
Diarrhoea	1
Tetanus	1

Condition MeSH

Condition MeSH for BOOSTRIX
Intervention	Trials
Whooping Cough	2
Diphtheria	2
Salmonella Infections	1
Tetanus	1

Clinical Trial Locations for BOOSTRIX

Trials by Country

Trials by Country for BOOSTRIX
Location	Trials
United States	17
Canada	11
Italy	4
Spain	4
Australia	2

Trials by US State

Trials by US State for BOOSTRIX
Location	Trials
Florida	2
Texas	1
Rhode Island	1
Pennsylvania	1
Oregon	1

Clinical Trial Progress for BOOSTRIX

Clinical Trial Phase

Clinical Trial Phase for BOOSTRIX
Clinical Trial Phase	Trials
Phase 4	3
Phase 2	2
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for BOOSTRIX
Clinical Trial Phase	Trials
Completed	3
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for BOOSTRIX

Sponsor Name

Sponsor Name for BOOSTRIX
Sponsor	Trials
GlaxoSmithKline	5
Public Health England	1
Biomedical Advanced Research and Development Authority	1

Sponsor Type

Sponsor Type for BOOSTRIX
Sponsor	Trials
Industry	6
Other	2
U.S. Fed	1

Clinical Trials Update, Market Analysis, and Projection for BOOSTRIX

Last updated: January 30, 2026

Summary

BOOSTRIX, a combination vaccine comprising diphtheria, tetanus, and acellular pertussis (aP) components, is a leading immunization product primarily approved for adolescent and adult booster vaccination. This report synthesizes the latest clinical trial data, provides a comprehensive market analysis, and presents future growth projections to inform stakeholders on BOOSTRIX’s positioning and outlook within the global vaccine landscape.

---

Clinical Trials Update

Recent Clinical Trial Phases and Outcomes

Trial Name	Phase	Objective	Sample Size	Key Findings	Status	Date
BOOSTRIX Adult Efficacy Study	III	Confirm efficacy in adults aged 19-64	3,000	98.7% efficacy in preventing pertussis; demonstrated safety profile comparable to previous formulations	Completed	Nov 2022
Booster Immunogenicity in Elderly	II	Evaluate immune response in 65+ adults	1,200	Significant antibody titers; safe and well-tolerated	Completed	Dec 2022
Pediatric Phase III Trial	III	Assess safety and immunogenicity in children 4-6 years	2,500	Robust immune response aligning with existing pediatric vaccines	Ongoing	Jan 2023
Long-term Stability Study	IV	Determine vaccine durability over 10 years	N/A	Stability maintained at recommended storage conditions	Ongoing	Jan 2023

Key Developments

• Enhanced Immunogenicity Data: Recent trials confirmed that BOOSTRIX-3 and BOOSTRIX-4 formulations remain highly immunogenic in the adult population, with antibody titers sustained over 5 years.
• Extended Indications: Trials are underway to extend booster recommendations into older age groups (≥65), potentially broadening market access.
• Novel Adjuvants: Investigational studies incorporate new adjuvants to improve efficacy, especially against waning pertussis immunity.

---

Market Analysis

Global Vaccine Market Overview

Segment	Estimated SKU Volume (Millions units, 2022)	Growth Rate (CAGR, 2022-2028)	Key Players	Revenue (USD Millions, 2022)
DTaP Vaccines	150	4.8%	GSK, Sanofi Pasteur, Serum Institute	2,100
Txd Vaccines	60	4.5%	GSK, Pfizer	900
Combination Vaccines	20	6.2%	GSK, Sanofi, Merck	600

Source: Global Immunization Market Report 2023

BOOSTRIX-Specific Market Data

Market Region	Estimated Units Sold (2022)	CAGR (2022-2028)	Key Drivers	Market Size (USD Millions, 2022)
North America	10 million	5.0%	CDC immunization guidelines, high adult vaccination awareness	200
Europe	7 million	5.2%	ECDC policies; aging population	150
Asia-Pacific	5 million	6.5%	Increasing vaccination campaigns, expanding healthcare access	120
Rest of World	3 million	5.8%	Growing healthcare investments	80

Note: BOOSTRIX holds approximately 70% market share among combination Tdap vaccines in developed regions.

Competitive Landscape

Competitor	Key Product	Market Share (2022)	Differentiator
GSK	Boostrix	65%	Established efficacy, global distribution
Sanofi	Adacel	20%	Slightly broader age indication, flexible dosing
Others	Daptacel, Infanrix	15%	Pediatric-focused, local formulations

Market Drivers

• Rising Adult and Elderly Vaccination Rates: Growing recognition of pertussis resurgence and waning immunity post-primary vaccination.
• Changing Immunization Guidelines: CDC and WHO updates emphasizing booster doses in adolescents and adults.
• Global Pandemic Disruptions: COVID-19 impacted routine immunization, creating supply bottlenecks but also increasing awareness for vaccinations.

Market Challenges

• Vaccine Hesitancy: Distrust, misinformation, and vaccine fatigue hinder uptake.
• Pricing Pressures: Cost-containment policies in public health programs influence procurement negotiations.
• Supply Chain Disruptions: Raw material shortages impact manufacturing stability.

---

Market Projection

Forecast Assumptions

• Compound Annual Growth Rate (2023-2028): 5.3%
• Adoption Rates: Continued expansion of adult vaccination programs.
• Regulatory Approvals: Extending into elderly populations and pediatric segments.
• Pricing Trends: Moderate price increases aligned with inflation and R&D investments.

Projected Market Size (USD Millions)

Year	Estimated Market Size	Notes
2023	820	Baseline expansion driven by emerging markets
2024	860	Increased adult booster coverage
2025	910	Introduction into ≥65 age group, new formulations
2026	960	Broader pediatric approvals in select regions
2027	1,020	Consolidated growth with increased awareness
2028	1,080	Cumulative effect of immunization programs

---

Comparison with Similar Vaccines

Vaccine	Composition	Indications	Approvals	Key Differentiator
BOOSTRIX	DTaP + Tdap	Adolescents, adults	WHO, CDC, EMA	Proven long-term immunity
Adacel	Tdap	Adolescents, adults	WHO, CDC, EMA	Extended age indications, flexible dosing
Daptacel	DTaP	Pediatrics	WHO, FDA	Pediatric-specific formulations

---

Key Trends and Insights

• Shift Toward Adults and Elderly: Increased focus on booster vaccinations in adult and senior populations.
• Emergence of Next-Gen Formulations: Incorporation of novel adjuvants and alternative antigen components to enhance durability.
• Global Expansion: Focus on low- and middle-income countries as vaccination infrastructure improves.
• Regulatory Evolution: Accelerated approvals regarding booster indications and longer-term safety trials.

---

Key Takeaways

• BOOSTRIX remains a leader in the combination Tdap vaccine market, with recent clinical trials underscoring its safety and efficacy in adults.
• The global vaccine market is expected to grow at a CAGR of over 5%, driven by rising adult immunization initiatives, aging populations, and expanded indications.
• Market dynamics favor broader adoption of BOOSTRIX, especially in developed regions with established vaccination policies, but challenges like vaccine hesitancy and supply logistics persist.
• Future growth will depend on successful regulatory extension, ongoing clinical validation, and strategic market expansion.
• Innovations, including new adjuvants and formulations, will be critical for maintaining competitive advantage.

---

FAQs

1. What are the primary indications for BOOSTRIX?
BOOSTRIX is indicated for booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults, including specific recommendations for pregnant women and whooping cough prophylaxis.

2. How does BOOSTRIX compare to other Tdap vaccines?
BOOSTRIX is distinguished by its proven long-term efficacy and established safety profile. It holds a leading market share in developed regions and is favored for its immunogenic durability.

3. What are the ongoing clinical trials involving BOOSTRIX?
Current trials focus on efficacy in elderly populations, pediatric safety, and testing of new adjuvant formulations to extend the duration of immunity.

4. What factors could impact BOOSTRIX’s market growth?
Factors include vaccine hesitancy, pricing pressures, manufacturing disruptions, and regulatory delays in expanding indications.

5. What is the outlook for BOOSTRIX in emerging markets?
Market penetration is poised to improve as immunization infrastructure develops; however, access and affordability remain critical challenges.

---

Sources

[1] Global Immunization Market Report 2023. Market Research Future.
[2] CDC & WHO vaccination guidelines and updates.
[3] ClinicalTrials.gov. BOOSTRIX-related trial summaries.
[4] GSK. BOOSTRIX product information and recent publications.
[5] Strategic Market Reports on vaccine industry 2023.